- Home
- TLRY vs ERAS Comparison
TLRY vs ERAS Comparison
Compare TLRY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | ERAS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLRY | ERAS |
|---|---|---|
| Price | $8.96 | $3.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $150.00 | $3.71 |
| AVG Volume (30 Days) | ★ 20.0M | 2.7M |
| Earning Date | 01-08-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $830,766,000.00 | N/A |
| Revenue This Year | $7.28 | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.31 | N/A |
| 52 Week Low | $3.51 | $1.01 |
| 52 Week High | $23.20 | $3.80 |
Technical Indicators
Market Signals| Indicator | TLRY | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 64.17 |
| Support Level | $9.82 | $3.39 |
| Resistance Level | $15.70 | $3.77 |
| Average True Range (ATR) | 1.45 | 0.25 |
| MACD | -0.51 | -0.02 |
| Stochastic Oscillator | 11.48 | 78.70 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.